NPR, October 6, 2014. The Masima device company created a Patient Safety Movement Foundation but didn’t investigate reports that its devices harmed patients. “When a company refuses to respond in any way to the FDA other than to say that the FDA is wrong on every issue, that’s not very credible,” Zuckerman said. “Especially when users made complaints that the company’s product put patients at risk,” she said.
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Not Enough Safety Testing On Medical Implant Devices, Studies Claim
CBS News, September 30, 2014. Every day, people receive medical implants — artificial valves, hip replacements, surgical mesh and the like — that may not have been rigorously tested before or after their approval by the U.S. Food and Drug Administration, two new studies contend.
Read More »Medical Devices Lack Safety Evidence, Study Finds
The Wall Street Journal, September 29, 2014. The majority of moderate to high-risk medical devices approved by the U.S. Food and Drug Administration lack publicly available scientific evidence to verify their safety and effectiveness despite requirements in the law, according to a study released Monday.
Read More »Can the War on Cancer Be Won? A Surprising Answer
Huffington Post, September 16, 2014. Better communication about treatment options will help millions of people avoid ever developing cancer, and also prevent unnecessarily radical and harmful treatments for those who are diagnosed with cancer.
Read More »FDA is Chastised Over its ‘Action Plan’ to Diversify Clinical Trial Participation
The Wall Street Journal, August 28, 2014: NCHR explains to WSJ that the FDA Diversity Action Plans lacks incentives for companies to study their medical products in a diverse group of patients, including sex, age, and race/ethnicity. The FDA urges diversity but approves drugs and implants that have only been evaluated on mostly white patients under 65.
Read More »